Core Viewpoint - The announcement highlights the successful administration of the drug Opalizumab (PD-L1/4-1BB bispecific antibody, LBL-024) to the first patient in a Phase Ib/II clinical trial for treating recurrent or metastatic triple-negative breast cancer [1] Group 1: Clinical Trial Details - The clinical trial is an open-label, multicenter Phase Ib/II study led by Professor Yin Yongmei from Jiangsu Provincial People's Hospital [1] - The trial is being conducted simultaneously across multiple hospitals nationwide [1] - The objective of the trial is to evaluate the efficacy and safety of Opalizumab administered alone or in combination with albumin-bound paclitaxel for patients with recurrent or metastatic triple-negative breast cancer [1]
维立志博-B(09887.HK)：维利信™用于治疗复发性或转移性三阴性乳腺癌的Ib/II期临床研究首例患者已成功用药